Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]
Residential aged care facilities need to tackle antipsychotic usage in dementia patients

Residential aged care facilities need to tackle antipsychotic usage in dementia patients

NPS MedicineWise has welcomed the recommendations of the recently released Senate Committee report on the care of Australians living with dementia and is encouraging residential aged care facilities to tackle the overuse of antipsychotics medicines in people with behavioural or psychological problems associated with dementia. [More]
Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. [More]

Geographical variation in antipsychotic efficacy not ruled out

An individual patient data meta-analysis fails to exclude the possibility that atypical antipsychotics work better in patients from some parts of the world than others. [More]
Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. [More]
State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

The Arkansas Supreme Court reversed a $1.2 billion judgment against Johnson & Johnson on Thursday, finding that the state attorney general erred by suing under a law that applied to health care facilities, not drug companies. The judgment, one of the largest in history for a state fraud case, was imposed in 2012 after a jury concluded that Johnson & Johnson had improperly marketed and concealed the risks of Risperdal, an antipsychotic drug (Thomas, 3/2). [More]
First Edition: March 21, 2014

First Edition: March 21, 2014

Today's early morning highlights from the major news organizations, including a new examination of Ezekiel Emanuel's book about the crafting of the health law and President Obama's latest push to boost enrollment. [More]

Primary negative symptoms worsen functioning in schizophrenia

Primary negative symptoms adversely affect social, vocational and recreational functioning in patients with schizophrenia, even when the potential influence of secondary negative symptoms has been accounted for, Canadian researchers report. [More]

EEG-based biomarker can help predict psychotic disorder in high-risk individuals

Only one third of individuals identified as being at clinical high risk for psychosis actually convert to a psychotic disorder within a 3 year follow-up period. This risk assessment is based on the presence of sub-threshold psychotic-like symptoms. [More]

Suicidal behaviour in schizophrenia may herald future violence

People with schizophrenia who threaten or attempt suicide have a propensity towards violence, UK researchers believe. [More]

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder. [More]
Administration reverses course on proposed Medicare drug changes

Administration reverses course on proposed Medicare drug changes

After advancing a number of changes to the Medicare Part D program earlier this year, the Centers for Medicare & Medicaid Services withdrew its plan, which had drawn significant opposition from patients, drug companies and lawmakers in both parties. [More]
First Edition: March 11, 2014

First Edition: March 11, 2014

Today's headlines include reports that the Centers for Medicare & Medicaid Services is stepping back from proposed changes to the Medicare drug program. [More]
Harvard Review of Psychiatry provides updates on ASD research

Harvard Review of Psychiatry provides updates on ASD research

Recent years have seen exciting progress in key areas of research on autism spectrum disorders (ASD): from possible genetic causes, to effective treatments for common symptoms and clinical problems, to promoting success for young people with ASD entering college. Updates on these and other advances in ASD research are presented in the March special issue of Harvard Review of Psychiatry. [More]
Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease. [More]

Medicare Part D cost-saving plan draws opposition on several fronts

Among other things, the proposal would limit the types of antidepressants -- and other kinds of drugs -- that are available to Medicare beneficiaries. Drug industry and insurer groups are lining up against the change. [More]

Further support for hippocampal volume as psychosis biomarker

Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes provide further evidence that reduced hippocampal volume is a consistent feature of schizophrenia. [More]
First Edition: February 27, 2014

First Edition: February 27, 2014

Today's headlines include a number of stories about Obama past and present administration officials -- notably, former Secretary of State Hillary Clinton and Vice President Joe Biden -- who are stepping up to "sell" people on enrolling in new health law insurance coverage. [More]

Adults with mental illness more likely to be victims of violence, says study

New research shows that almost one-third of adults with mental illness are likely to be victims of violence within a six-month period, and that adults with mental illness who commit violence are most likely to do so in residential settings. [More]

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

‚ÄčAn antidepressant medication has shown potential in treating symptoms of agitation that occur with Alzheimer's disease and in alleviating caregivers' stress, according to a multi-site U.S.- Canada study. [More]